

1 **Clinical Practice Guideline: Debridement of Skin, Muscle and/or Fascia, or**
2 **Bone in the Lower Extremities**

3
4 **Date of Implementation: August 18, 2016**

5
6 **Product: Specialty**
7
8

9 **GUIDELINES**

10 A. American Specialty Health – Specialty (ASH) considers services consisting of CPT
11 Code 11000 and 11001 to be medically necessary for the treatment of extensive
12 eczematous or infected skin **upon meeting ALL of the following criteria:**

- 13 1. Presence of condition(s) that may require debridement of large amounts of skin (at
14 least one of the following):
 - 15 • Rapidly spreading necrotizing process (e.g., aggressive streptococcal
16 infections);
 - 17 • Severe eczema;
 - 18 • Bullous skin diseases;
 - 19 • Extensive skin trauma (including large, abraded areas with ground-in dirt); OR
 - 20 • Autoimmune skin diseases (such as pemphigus).
- 21
- 22 2. All significant relevant comorbid conditions are addressed that could interfere with
23 optimal wound healing.
- 24
- 25 3. If there is no necrotic, devitalized, fibrotic, or other tissue or foreign matter present
26 that would interfere with wound healing, the debridement service is not medically
27 necessary. The presence or absence of such tissue or foreign matter must be
28 documented in the medical record.

29
30 The number of debridement services required is variable and depends on numerous
31 intrinsic and extrinsic factors.

32
33 Local infiltration, metatarsal/digital block or topical anesthesia are included in the
34 reimbursement for debridement services and are not separately payable. Anesthesia
35 administered by or incident to the provider performing the debridement procedure is
36 not separately payable.

37
38 **Exclusion criteria:** CPT code 11000 and 11001 is **NOT** appropriate for the following
39 conditions:

- 40 • Debridement of a localized amount of tissue normally associated with a
41 circumscribed lesion. Examples of this are ulcers, furuncles, and localized skin
42 infections.

- 1 • Skin breakdown under a dorsal corn is not considered an ulcer and generally does
2 not require debridement. These lesions typically heal without significant surgical
3 intervention beyond removal of the corn and shoe modification.
- 4 • Removing a collar of callus (hyperkeratotic tissue) around an ulcer is not
5 debridement of skin or necrotic tissue.

6
7 ASH considers **CPT code 17250** (Chemical cauterization of granulation tissue [i.e., proud
8 flesh]) an integral service as part of a health care provider’s medical or surgical care and
9 not separately billable with surgical debridement CPT codes listed in the table below.

10
11 **CPT CODES AND DESCRIPTIONS**

CPT® Code	CPT® Code Description
11000	Debridement of extensive eczematous or infected skin; up to 10% of body surface
11001	Debridement of extensive eczematous or infected skin; each additional 10% of the body surface, or part thereof (List separately in addition to code for primary procedure)
17250	Chemical cauterization of granulation tissue (i.e., proud flesh)

12
13 **BACKGROUND**

14 Debridement is the removal of infected, contaminated, damaged, devitalized, necrotic, or
15 foreign tissue from a wound. The services described in this clinical practice guideline cover
16 debridement of skin, subcutaneous tissue, fascia, muscle, bone and removal of foreign
17 material. Debridement promotes wound healing by reducing sources of infection and other
18 mechanical impediments to healing. Its goal is to cleanse the wound, reduce bacterial
19 contamination and provide an optimal environment for wound healing or possible surgical
20 intervention. The usual end point of debridement is removal of pathological tissue and/or
21 foreign material until healthy tissue is exposed. Debridement techniques include, among
22 others, sharp and blunt dissection, curettement, scrubbing, and forceful irrigation. Surgical
23 instruments may include a scrub brush, irrigation device, electrocautery, laser, sharp
24 curette, forceps, scissors, burr or scalpel.

25
26 Conditions that may require debridement of large amounts of skin are aggressive
27 infections, severe eczema, and certain autoimmune skin diseases.^{[1][2]} The Infectious Disease
28 Society of America (IDSA) recommends surgical debridement as a component of a
29 multimodal treatment plan including broad-spectrum antibiotics and empirical therapy for
30 patients with complicated deeper soft-tissue infections, surgical/traumatic wound infection,
31 major abscesses, cellulitis, and infected ulcers and burns (Liu et al., 2011).

1 Foot infections are a common and serious problem in persons with diabetes. Diabetic foot
 2 infections (DFIs) typically begin in a wound, most often a neuropathic ulceration. While
 3 all wounds are colonized with microorganisms, the presence of infection is defined by ≥ 2
 4 classic findings of inflammation or purulence. The IDSA (Lipsky et al., 2012) recommends
 5 debridement within a multimodal care plan. Debridement, aimed at removing debris,
 6 eschar, and surrounding callus. Sharp (or surgical) methods were generally considered best,
 7 but mechanical, autolytic, or larval debridement techniques were recommended as
 8 appropriate for some wounds. The specific course of care for the patient needs to be
 9 determined on a case-by-case basis.

10
 11 **Bullous Disorders**

12 Bullous disorders are characterized by blisters or erosions of the skin and mucous
 13 membranes. The type of disease depends upon the level in the skin in which the blisters
 14 form and where they are located on the body. Bullous skin disorders may be acquired or
 15 induced, or they may be autoimmune in origin. These disorders are not contagious.

16
 17 Bullous disease of diabetes (bullosis diabeticorum) is a distinct, spontaneous,
 18 noninflammatory, blistering condition of acral skin that is unique to patients with diabetes
 19 mellitus. Specific treatment of bullous disease of diabetes (bullosis diabeticorum) is
 20 unnecessary because the condition is self-limiting. The blister should be left intact
 21 whenever possible to serve as a sterile dressing and to avoid secondary infection. However,
 22 secondary tissue necrosis may require debridement and possible tissue grafting (Poh-
 23 Fitzpatrick et al., 2013).

24
 25 **Pressure Injury**

26 A pressure injury is defined as localized damage to the skin and/or underlying tissue as a
 27 result of pressure or pressure in combination with shear. These injuries usually occur over
 28 a bony prominence but may also occur due to injury from a medical device or other object
 29 (National Pressure Injury Advisory Panel, 2019). Because muscle and subcutaneous tissue
 30 are more susceptible to pressure induced injury than dermis and epidermis, pressure
 31 injuries are often worse than their initial presentation. Pressure injuries are assessed and
 32 staged at the bedside as a clinical description of the depth of observable tissue destruction.

33
 34 For the purpose of this clinical practice guideline, the staging of pressure injuries can be
 35 classified according to the National Pressure Injury Advisory Panel as follows (Berlowitz,
 36 2023):

37

Pressure Injury Stage	Description
(Suspected) Deep Tissue Injury	Deep tissue pressure injury is characterized as intact or non-intact skin with a localized area of persistent non-blanchable deep red, maroon, purple discoloration, or

Pressure Injury Stage	Description
	epidermal separation revealing a dark wound bed or blood-filled blister. Pain and temperature change often precede skin color changes. Discoloration may appear differently in darkly pigmented skin. This injury results from intense and/or prolonged pressure and shear forces at the bone-muscle interface. The wound may evolve rapidly to reveal the actual extent of tissue injury or may resolve without tissue loss.
Stage 1	Intact skin with a localized area of non-blanchable erythema, which may appear differently in darkly pigmented skin. The presence of blanchable erythema or changes in sensation, temperature, or firmness may precede visual changes. Color changes do not include purple or maroon discoloration; these may indicate deep tissue pressure injury.
Stage 2	Partial-thickness loss of skin with exposed dermis. The wound bed is viable, pink or red, moist, and may also present as an intact or ruptured serum-filled blister. Adipose tissue is not visible and deeper tissues are not visible. Granulation tissue, slough, and eschar are not present. These injuries commonly result from adverse microclimate and shear in the skin over the pelvis and shear in the heel.
Stage 3	Full-thickness loss of skin, in which adipose tissue is visible in the ulcer and granulation tissue and epibole are often present. Slough and/or eschar may be visible. The depth of tissue damage varies by anatomical location; areas of significant adiposity can develop deep wounds. Undermining and tunneling may occur. Fascia, muscle, tendon, ligament, cartilage, and/or bone are not exposed. If slough or eschar obscures the extent of tissue loss, this is an unstageable pressure injury.
Stage 4	Full-thickness skin and tissue loss with exposed or directly palpable fascia, muscle, tendon, ligament, cartilage, or bone in the ulcer. Slough and/or eschar may be visible. Epibole, undermining, and/or tunneling often occur. Depth varies by anatomical location. If slough or eschar obscures the extent of tissue loss, this is an unstageable pressure injury.

Pressure Injury Stage	Description
Unstageable	Full-thickness skin and tissue loss in which the extent of tissue damage within the ulcer cannot be confirmed because it is obscured by slough or eschar. If slough or eschar is removed, a stage 3 or stage 4 pressure injury will be revealed. Stable eschar (i.e., dry, adherent, intact without erythema or fluctuance) on the heel or ischemic limb should not be softened or removed.

1
2 The National Pressure Injury Advisory Panel (2019) recommends debridement of non-
3 viable, necrotic, or infected tissue within the wound bed or edge of pressure injuries when
4 appropriate to the individual’s condition and consistent with the overall goals of care.

5 6 **Necrotizing Fasciitis**

7 Necrotizing Fasciitis (NF) is a necrotizing soft tissue infection involving the fascia and
8 subcutaneous tissue that can cause rapid local tissue necrosis and life-threatening severe
9 sepsis. Accurate assessment and timely intervention are critical in the treatment of patients
10 affected with NF. Understanding the history and unique characteristics of this disease is
11 crucial to achieve early recognition, effective treatment and a favorable outcome. Classic
12 symptoms include severe pain out of proportion to local findings, erythema, mottling,
13 crepitus, skin anesthesia, warmth, tenderness, hemorrhagic bullous formation, edema in the
14 affected area and fever. Machado et al. (2011) reviewed the management of patients with
15 necrotizing fasciitis. Radical surgical debridement, broad spectrum antibiotics, negative
16 pressure wound dressings, and hyperbaric oxygen therapy are considered to be the
17 cornerstone of treatment. The mortality rate ranges widely from 10% to 75% and is related
18 to delay in initial debridement, and other factors such as patient age of more than 60 years,
19 associated hypotension, acidosis, bacteremia, renal failure, hyponatremia, peripheral
20 vascular disease, myonecrosis and myositis. The authors concluded that delay in
21 recognition and effective treatment of necrotizing fasciitis increases the mortality.
22 Therefore, prompt radical surgical debridement, appropriate antibiotics and adjuvant
23 therapy contribute to an improved outcome.

24 25 **PRACTITIONER SCOPE AND TRAINING**

26 Practitioners should practice only in the areas in which they are competent based on their
27 education, training and experience. Levels of education, experience, and proficiency may
28 vary among individual practitioners. It is ethically and legally incumbent on a practitioner
29 to determine where they have the knowledge and skills necessary to perform such services
30 and whether the services are within their scope of practice.

31
32 It is best practice for the practitioner to appropriately render services to a member only if
33 they are trained, equally skilled, and adequately competent to deliver a service compared

1 to others trained to perform the same procedure. If the service would be most competently
 2 delivered by another health care practitioner who has more skill and training, it would be
 3 best practice to refer the member to the more expert practitioner.

4
 5 Best practice can be defined as a clinical, scientific, or professional technique, method, or
 6 process that is typically evidence-based and consensus driven and is recognized by a
 7 majority of professionals in a particular field as more effective at delivering a particular
 8 outcome than any other practice (Joint Commission International Accreditation Standards
 9 for Hospitals, 2020).

10
 11 Depending on the practitioner’s scope of practice, training, and experience, a member’s
 12 condition and/or symptoms during examination or the course of treatment may indicate the
 13 need for referral to another practitioner or even emergency care. In such cases it is prudent
 14 for the practitioner to refer the member for appropriate co-management (e.g., to their
 15 primary care physician) or if immediate emergency care is warranted, to contact 911 as
 16 appropriate. See the *Managing Medical Emergencies (CPG 159 – S)* policy for
 17 information.

18 19 **References**

20 American College of Foot and Ankle Surgeons (ACFAS) Cosmetic Surgery Position
 21 Statement (2020). Retrieved on September 1, 2023 from:
 22 <https://www.acfas.org/policypositionstatements/>
 23

24 American Medical Association. (current year). Current Procedural Terminology (CPT)
 25 Current year (rev. ed.). Chicago: AMA
 26

27 Berlowitz, D. (2023). Clinical staging and management of pressure-induced skin and soft
 28 tissue injury. UpToDate. Retrieved on September 1, 2023 from
 29 [https://www.uptodate.com/contents/clinical-staging-and-management-of-pressure-](https://www.uptodate.com/contents/clinical-staging-and-management-of-pressure-induced-skin-and-soft-tissue-injury)
 30 [induced-skin-and-soft-tissue-injury](https://www.uptodate.com/contents/clinical-staging-and-management-of-pressure-induced-skin-and-soft-tissue-injury)
 31

32 Cabeza de Vaca, F. G., Macias, A. E., Ramirez, W. A., Munoz, J. M., Alvarez, J. A.,
 33 Mosqueda, J. L., Sifuentes-Osornio, J. (2010). Salvaging diabetic foot through
 34 debridement, pressure alleviation, metabolic control, and antibiotics Cabeza de Vaca
 35 et al. Salvaging diabetic foot. *Wound Repair & Regeneration*, 18(6), 567-571. doi:
 36 10.1111/j.1524-475X.2010.00621.x
 37

38 Centers for Medicare & Medicaid Services. Local Coverage Article: Billing and Coding:
 39 Debridement Services (A56617). Retrieved on September 1, 2023 from
 40 [https://www.cms.gov/medicare-coverage-database/details/article-](https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleId=56617&ver=19&LCDId=33614&bc=AAAAAAAAIAAA&)
 41 [details.aspx?articleId=56617&ver=19&LCDId=33614&bc=AAAAAAAAIAAA&](https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleId=56617&ver=19&LCDId=33614&bc=AAAAAAAAIAAA&)

- 1 Centers for Medicare & Medicaid Services. Local Coverage Article: Billing and Coding:
2 Wound Care (A55818). Retrieved on September 1, 2023 from
3 [https://www.cms.gov/medicare-coverage-](https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=55818&ver=17&bc=0)
4 [database/view/article.aspx?articleid=55818&ver=17&bc=0](https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=55818&ver=17&bc=0)
5
- 6 Centers for Medicare & Medicaid Services. Local Coverage Determination: Debridement
7 Services (L33614). Retrieved on September 1, 2023 from
8 [https://www.cms.gov/medicare-coverage-database/details/lcd-](https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=33614)
9 [details.aspx?LCDId=33614](https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=33614)
10
- 11 Centers for Medicare & Medicaid Services. Local Coverage Determination: Wound Care
12 (L37166). Retrieved on September 1, 2023 from [https://www.cms.gov/medicare-](https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=37166&ver=22&bc=AAAAAAABIAAA&)
13 [coverage-database/details/lcd-](https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=37166&ver=22&bc=AAAAAAABIAAA&)
14 [details.aspx?LCDId=37166&ver=22&bc=AAAAAAABIAAA&](https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=37166&ver=22&bc=AAAAAAABIAAA&)
15
- 16 Damoiseaux, J. (2013). Bullous skin diseases: classical types of autoimmune diseases.
17 *Scientifica* (Cairo), 2013, 457982. doi: 10.1155/2013/457982
18
- 19 Debridement Procedures for Managing Diabetic Foot Ulcers: A Review of Clinical
20 Effectiveness, Cost-effectiveness, and Guidelines. (2014). Ottawa ON: 2014 Canadian
21 Agency for Drugs and Technologies in Health
22
- 23 Dryden, M. S. (2010). Complicated skin and soft tissue infection. *J Antimicrob Chemother*,
24 65 Suppl 3, iii35-44. doi: 10.1093/jac/dkq302
25
- 26 Edsberg, L. E., Black, J. M., Goldberg, M., McNichol, L., Moore, L., & Sieggreen, M.
27 (2016). Revised national pressure ulcer advisory panel pressure injury staging system:
28 Revised pressure injury staging system. *Journal of Wound, Ostomy, and Continence*
29 *Nursing*, 43(6), 585–597. <https://doi.org/10.1097/WON.0000000000000281>
30
- 31 Faglia, E., Clerici, G., Caminiti, M., Quarantiello, A., Gino, M., & Morabito, A. (2006).
32 The role of early surgical debridement and revascularization in patients with diabetes
33 and deep foot space abscess: retrospective review of 106 patients with diabetes. *Journal*
34 *of Foot & Ankle Surgery*, 45(4), 220-226
35
- 36 Fisher, T. K., Scimeca, C. L., Bharara, M., Mills, J. L., Sr., & Armstrong, D. G. (2010). A
37 step-wise approach for surgical management of diabetic foot infections. *J Vasc Surg*,
38 52(3 Suppl), 72S-75S. doi: 10.1016/j.jvs.2010.06.011
39
- 40 Haycocks, S., & Chadwick, P. (2012). Debridement of diabetic foot wounds. *Nursing*
41 *Standard*, 26(24), 51-51-52, 54, 56 passim

- 1 Joint Commission International. (2020). Joint Commission International Accreditation
2 Standards for Hospitals (7th ed.): Joint Commission Resources
3
- 4 Kane, D. (2014). Surgical Management of Pressure Ulcers. In M. D. D. R. Thomas & M.
5 D. G. A. Compton (Eds.), *Pressure Ulcers in the Aging Population* (Vol. 1, pp. 99-126):
6 Humana Press
7
- 8 Kneisel, A., & Hertl, M. (2011). Autoimmune bullous skin diseases. Part 1: Clinical
9 manifestations. *J Dtsch Dermatol Ges*, 9(10), 844-856; quiz 857. doi: 10.1111/j.1610-
10 0387.2011.07793.x
11
- 12 Lebrun, E., Tomic-Canic, M., & Kirsner, R. S. (2010). The role of surgical debridement in
13 healing of diabetic foot ulcers. *Wound Repair Regen*, 18(5), 433-438. doi:
14 10.1111/j.1524-475X.2010.00619.x
15
- 16 Lipsky, B. A., Berendt, A. R., Cornia, P. B., Pile, J. C., Peters, E. J., Armstrong, D. G.,
17 Infectious Diseases Society of, A. (2012). 2012 Infectious Diseases Society of America
18 clinical practice guideline for the diagnosis and treatment of diabetic foot infections.
19 *Clin Infect Dis*, 54(12), e132-173. doi: 10.1093/cid/cis346
20
- 21 Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Chambers,
22 H. F. (2011). Clinical Practice Guidelines by the Infectious Diseases Society of
23 America for the Treatment of Methicillin-Resistant *Staphylococcus Aureus* Infections
24 in Adults and Children. *Clinical Infectious Diseases*. doi: 10.1093/cid/ciq146
25
- 26 Machado, N. O. (2011). Necrotizing fasciitis: The importance of early diagnosis, prompt
27 surgical debridement and adjuvant therapy. *North Am J Med Sci*, 3, 107-118
28
- 29 National Pressure Injury Advisory Panel, European Pressure Ulcer Advisory Panel & Pan
30 Pacific Pressure Injury Alliance. 2019. Prevention and treatment of pressure
31 ulcers/injuries: Clinical practice guideline. The international guideline.
32 EPUAP/NPIAP/PPPIA
33
- 34 Poh-Fitzpatrick MB, Junkins-Hopkins JM. Bullous disease of diabetes. Availabe at:
35 <http://emedicine.medscape.com/article/1062235-overview>. Accessed March 12, 2013
36
- 37 Ricco, J. B., Thanh Phong, L., Schneider, F., Illuminati, G., Belmonte, R., Valagier, A., &
38 Regnault De La Mothe, G. (2013). The diabetic foot: a review. *J Cardiovasc Surg*
39 (Torino), 54(6), 755-762
40
- 41 Roje, Z., Roje, Z., Matic, D., Librenjak, D., Dokuzovic, S., & Varvodic, J. (2011).
42 Necrotizing fasciitis: literature review of contemporary strategies for diagnosing and

- 1 management with three case reports: torso, abdominal wall, upper and lower limbs.
2 World J Emerg Surg, 6(1), 46. doi: 10.1186/1749-7922-6-46
3
4 Shahi, N., Bradley, S., Vowden, K., & Vowden, P. (2014). Diabetic bullae: a case series
5 and a new model of surgical management. J Wound Care, 23(6), 326, 328-330. doi:
6 10.12968/jowc.2014.23.6.326
7
8 Swanson, T., Asimus, M., & McGuiness, B. (2014). Wound Management for the Advanced
9 Practitioner: IP Communications Pty, Limited